Show simple item record

dc.contributor.authorCaly, Leon et al.
dc.date.accessioned2020-04-09T05:33:34Z
dc.date.available2020-04-09T05:33:34Z
dc.date.issued2020-04-03
dc.identifier.urihttps://doi.org/10.1016/j.antiviral.2020.104787en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/988
dc.description.abstractAlthough several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectInfectious Diseasesen_US
dc.subjectIvermectinen_US
dc.subjectParasitic Diseasesen_US
dc.titleThe FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitroen_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeOther publicationsen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalAntiviral Researchen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record